spacer
home > pmps > autumn 2017 > handling hazards
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Handling Hazards

The pharmaceutical industry’s ongoing search for new medicines capable of achieving greater therapeutic activity while also reducing dosage amounts and minimising undesirable side effects has led to an intense research focus on more potent drug molecules. As a result, the number of highly potent active pharmaceutical ingredients (HPAPIs) under development over the past few years has been steadily increasing, with HPAPIs present in around a quarter of medicines in the pharma pipeline (1).

The increasing demand from the oncology sector has been driving this growth, with around 60% of HPAPIs being developed as anticancer agents (1). With HPAPIs increasingly being used to treat chronic diseases such as diabetes and heart disease, this global market is expected to be worth an estimated $34.8 billion by 2025, up from $14.4 billion in 2016, according to figures from Grand View Research (2).

Highly Potent and Challenging

As HPAPIs are able to produce greater pharmacological effects at lower concentrations, smaller amounts of the drug can be administered to patients, potentially leading to fewer side effects as well as causing less damage to healthy tissue surrounding the diseased area. Furthermore, as lower administration frequencies can be used, patient adherence to medication schemes can potentially be improved. However, the greater potency of HPAPIs also presents several additional challenges to developers and manufacturers in terms of their safe handling.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As a qualified individual for investigational medicinal products and APIs with over 25 years’ experience within the sector, Carla Brandolini is a Senior GMP QA Specialist at Aptuit, responsible for ensuring and overseeing GMP compliance and batch release. She is also an expert in dealing with regulatory authority audits and follow-ups, as well as the management of controlled substances used for clinical and toxicological studies.

With over 20 years’ experience in the pharma industry, Jean-Francois Carniaux is a highly skilled PhD-trained scientist, whose expertise focuses on API analytical and chemistry development programmes, from early development to late clinical phase and commercial manufacture. As Director of API Development and Manufacturing for the Aptuit site in Verona, Italy, he combines technical expertise in chemical development, including solid-state chemistry and scale-up troubleshooting, with a breath of experience in project leadership and management.

As Vice President, Global Head of CMC for Aptuit, Mario Maio blends scientific knowledge with business acumen, leading his team to provide development expertise for all CMC disciplines and cGMP manufacturing. During his 25-year career, he has developed and monitored early- and late-stage formulation projects and provided strategic direction for the implementation of drug delivery systems, translating innovative ideas into products.

Starting his career in 1996 as a quality co-ordinator, Iain Rusling has gathered a wealth of skills and experience working with some of the biggest companies in the industry, leading him to become Vice President of Global Quality Management and EHS at Aptuit. Iain is an expert in quality management processes thanks to his long-standing experience in different cGMP environments, allowing him to drive initiatives, foster continuous improvement and maintain high levels of accountability throughout the entire area of responsibility.
spacer
Carla Brandolini, Jean-Francois Carniaux, Mario Maio and Iain Rusling
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Automated testing of pharmaceutical packaging

Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 
Industry Events

BIO-Europe 2018-24th Annual International Partnering Conference

5-7 November 2018, Bella Center Copenhagen, Denmark

The 24th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement